Growth financing Penfund specializes in junior capital for middle market North American companies and recently expanded with new debt fund launches, indicating ongoing capacity for growth-oriented financing needs such as unitranche, second lien, and subordinated debt for portfolio companies.

Portfolio expansion Active investment activity across diverse sectors and recurring fund cycles (Fund VII and Penfund Prime) suggests continued appetite for add-on acquisitions, recapitalizations, and growth equity in mid-market firms seeking capital structure optimization.

Recent transactions Recent investments in DOCS Dermatology, CBI Health, Recochem, Mariner Wealth Advisors, and 24-7 Intouch demonstrate familiarity with healthcare services, financial services, consumer/retail-adjacent and services sectors—potential targets for similar financing solutions.

Strategic partnerships Penfund’s capital comes from pension funds, insurers, banks, family offices and high net worth individuals, and the firm is management-owned, signaling a stable, relationship-driven approach suitable for fund-level co-investments and long-term financing engagements with growth-stage companies.

Scale and health With assets under management of approximately $3.5 billion and a track record of over $4.3 billion invested across 75+ deals, Penfund offers credible capital capacity and proven execution, making it a strong partner for mid-market lenders, financial sponsors, and portfolio company restructurings seeking reliable junior-capital solutions.